Celltrion executive Kim Hyoung-ki said that the company expects to sell Remsima (biosiimiliar Drug of Remicade) at a 30 percent discount to Remicade, aiming to win a significant chunk of the $6.1 billion sales that the drug racked up for Johnson & Johnson in 2012.好大口气。展开全文 原微博
BAD NEWS OR GOOD? Drugmakers can count compulsory licensing among the new pitfalls of China's huge-and-growing drug market. Thanks to amended intellectual property laws, the Chinese government can now force generic drugs onto the market before branded meds lose patent protection.展开全文 原微博